Navigation Links
EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Date:10/25/2007

inst a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. Data from previous studies with MKC-1 demonstrate broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models. MKC-1 has been shown to inhibit mitotic spindle formation, prevent chromosome segregation in the M-phase (mitosis) of the cell cycle, and induce apoptosis. Furthermore, MKC-1 inhibits the Akt-mTOR signaling pathways, which may occur through inhibition of the mTOR/rictor pathway. The Akt-mTOR pathway is the most frequently mutated pathway in human tumors and mutations have been shown to promote tumor progression and decrease survival in cancer patients.

Mark R. Bray, Ph.D., EntreMed Vice President, Research, commented on the results, "Data from preclinical studies with MKC-1 continue to support its therapeutic potential in a variety of tumor types. The data are consistent with MKC-1 targeting the mTOR pathway by a mechanism that is distinct from rapamycin-like agents, such as Temosirolimus. These results, along with the recent success of agents that target the mTOR pathway, provide validation that clinical studies with MKC-1 in cancers such as renal cell are warranted. MKC- 1 is currently in clinical trials in metastatic breast cancer, non-small cell lung cancer, and leukemia."

To view the poster presentation, visit the Company's web site at http://www.entremed.com.

Sutent(R) is a registered trademark of its owner and is not a registered trademark of EntreMed, Inc.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studie
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
8. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Warner Chilcott plc (Nasdaq: WCRX ) today ... "Company") has commenced a cash tender offer, on ... forth in the Company,s Offer to Purchase and ... "Offer to Purchase"), for any and all of ... (the "Notes"). ,, The Company is also soliciting ...
(Date:12/15/2009)... LAKE CITY, Dec. 15 Sonic Innovations, ... care services and solutions, donated $10,000 to its ... Monday, Dec. 14, 2009. ,, Sonic Innovations President ... local Feeding America member, the Utah Food Bank, ... Sonic employees also participated in an office food ...
(Date:12/15/2009)... KV Pharmaceutical Company ( KVa/KVb) today announced that on ... (the "Notice") executed by the Marc S. Hermelin Revocable ... that the Board of Directors of the Company (the ... written consent relating to the proposed appointment of John ... Ronald J. Kanterman,s departure (the "Director Appointment"). ,, As ...
Breaking Medicine Technology:Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 2Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 3Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 4Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 5Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 6Sonic Innovations, Inc. Donates $10,000 to Feeding America 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 7Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress 3B Emotional Issues can be a Significant Contributing Factor 60921 1Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress 3B Emotional Issues can be a Significant Contributing Factor 60921 2Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress 3B Emotional Issues can be a Significant Contributing Factor 60921 3Family Research Council Praises Passage of Pro life Amendment to Health Care Bill 60916 1Family Research Council Praises Passage of Pro life Amendment to Health Care Bill 60916 2AMA Hails House Passage of Health Reform Bill 28H R 3962 29 60911 1AMA Hails House Passage of Health Reform Bill 28H R 3962 29 60911 2
... SKOKIE, Ill., Dec. 2 Horizon ... today announced that two pivotal,Phase 3 ... candidate, HZT-501,met all primary endpoints. HZT-501, ... ibuprofen and famotidine, demonstrated a,statistically significant ...
... 1 TargeGen has announced that an oral,presentation of preliminary results from a multi-center, US-based ... (ASH) Meeting. , , Details of the presentation are as follows:, ... A Phase I Study of TG101348, an Orally Bioavailable, ... JAK2-Selective Inhibitor, in Patients with, ...
Other Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4
(Date:12/16/2009)... in all of the Florida Whole Foods store. , ... ... hair transplant and hair loss physician , is pleased to announce ... Protein Shake. Dr. Shapiro developed the all natural growth-hormone free, hair ... out and muscle building., , , , ,The Whole Foods grocery chain ...
(Date:12/15/2009)... 15 The failure of the U.S. ... cut costs, much less the more effective direct ... latest example of how big industry controls the ... proposed drug amendment by Senator Dorgan (D-ND) was ... campaign pledge to allow Medicare to directly negotiate ...
(Date:12/15/2009)... NAPA, Calif., Dec. 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences ... healthy aging, today announced that shareholders had approved all three resolutions that the Company had ... were as follows: , , Description of ... Votes ... For ...
(Date:12/15/2009)... for lying about taxes in the healthcare bill ... earned a place under the "Naughty" column on Americans for ... being caught telling a brazen lie on the floor of ... would not raise taxes. ,, Speaking on the U.S. ... " I have also heard it argued ...
(Date:12/15/2009)... 15 Vitech Systems Group, a leading ... (CRM) software, announced today that it has completed ... the Screen Actors Guild-Producers Pension & Health Plans ... service capabilities to SAG-PH call center personnel in ... installed using Vitech,s V3 Benefits Administration System which ...
Breaking Medicine News(10 mins):Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 2Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 3Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2
... Jan. 12 Align Technology,Inc. (Nasdaq: ALGN ... Administration,(FDA) has cleared new labeling for the Invisalign system, ... use. In addition,certain conditions previously listed as contraindications ... "Over the years, our customers have demonstrated that ...
... Denmark, Jan. 12 Wyeth Pharmaceuticals, a division of ... today announced that the companies have entered into a ... medicines based on Santaris Pharma,s proprietary Locked Nucleic Acid ... of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a ...
... home a special place for,family and friends, Kimberly-Clark Corporation ... of the Room-A-Day Giveaway sweepstakes to award 16 lucky,winners ... and Host,of Dress My Nest,s, Thom Filicia, on behalf ... View", and reveal his transformation of the,show,s out-dated dressing ...
... IL, Jan. 12 /PRNewswire-FirstCall/ - SXC Health Solutions Corp. ... TSX: SXC), a leading provider of pharmacy benefit management ... unit has been awarded a three-year contract to provide ... Benefit Trust (UFCW Trust) based in Walnut Creek, California. ...
... and CORONA, Calif., Jan. 12 ,Watson Pharmaceuticals, Inc. ... Limited (Nasdaq:, WCRX ) announced today that ... resolve pending patent litigation related to Warner Chilcott,s,oral ... Separately,Warner Chilcott and Watson have entered into a ...
... Q12h and Q8h Regimens Deliver Robust Antiviral Effects and ... in Q2 2009 -- Conference call today at 8:30 ... InterMune, Inc. (Nasdaq: ITMN ) today reported ... its Phase 1b clinical trial of ITMN-191 (R7227) in ...
Other Medicine News:Health News:FDA Clears Expanded Labeling for the Invisalign System 2Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 2Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 3Health News:Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines 4Health News:Kimberly-Clark and ABC's 'The View' Award $400,000 for Room Makeovers in the Room-A-Day Giveaway Sweepstakes 2Health News:Kimberly-Clark and ABC's 'The View' Award $400,000 for Room Makeovers in the Room-A-Day Giveaway Sweepstakes 3Health News:SXC Health Solutions selected by UFCW & Employers Benefit Trust to provide PBM services 2Health News:Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 2Health News:Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 3Health News:Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 4Health News:Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 5Health News:InterMune Reports Results from Triple Combination Study of ITMN-191 2Health News:InterMune Reports Results from Triple Combination Study of ITMN-191 3Health News:InterMune Reports Results from Triple Combination Study of ITMN-191 4Health News:InterMune Reports Results from Triple Combination Study of ITMN-191 5Health News:InterMune Reports Results from Triple Combination Study of ITMN-191 6
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: